SCHEMBL154178

SCHEMBL154178

N#Cc1ccc(N2CCCC2)cc1

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.68
TP53 P04637 2/20 0.68
CHRNA10 Q9GZZ6 1/20 0.56
CHRNA9 Q9UGM1 1/20 0.56
ALDH1A1 P00352 5/20 0.52
MEN1 O00255 2/20 0.52
MAPT P10636 2/20 0.52
KMT2A Q03164 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
LMNA P02545 1/20 0.48
HSP90AA1 P07900 1/20 0.48
CCR6 P51684 1/20 0.48
CACNA1B Q00975 1/20 0.48
APBA1 Q02410 1/20 0.48
APOBEC3G Q9HC16 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
POLB P06746 2/20 0.48
NPC1 O15118 1/20 0.48
USP2 O75604 1/20 0.48
GAA P10253 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL139427 0.98 KDM4E (0.66) KDM4ETP53CHRNA10CHRNA9ALDH1A1
SCHEMBL149656 0.98 KDM4E (0.66) KDM4ETP53CHRNA10CHRNA9ALDH1A1
SCHEMBL7402909 0.95 KDM4E (0.68) KDM4ETP53CHRNA10CHRNA9ALDH1A1
SCHEMBL2234557 0.92 KDM4E (0.59) KDM4ETP53CHRNA10CHRNA9ALDH1A1
SCHEMBL13098159 0.92 KDM4E (0.59) KDM4ETP53CHRNA10CHRNA9ALDH1A1
SCHEMBL2384959 0.91 KDM4E (0.80) KDM4ETP53CHRNA10CHRNA9ALDH1A1
SCHEMBL18409049 0.89 KDM4E (0.56) KDM4ETP53CHRNA10CHRNA9ALDH1A1
SCHEMBL12071033 0.89 KDM4E (0.56) KDM4ETP53CHRNA10CHRNA9ALDH1A1
SCHEMBL19648941 0.89 KDM4E (0.56) KDM4ETP53CHRNA10CHRNA9ALDH1A1
SCHEMBL12635874 0.89 KDM4E (0.56) KDM4ETP53CHRNA10CHRNA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12605450-B2 C3-carbon linked glutarimide Degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2026-04-21 US disclosed
EP-4717317-A2 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION C4 Therapeutics, Inc. (US) 2026-04-01 EP disclosed
US-12570626-B2 Degraders and degrons for targeted protein degradation C4 THERAPEUTICS, INC. (US) 2026-03-10 US disclosed
EP-3641762-B1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION C4 THERAPEUTICS INC (US) 2026-02-18 EP disclosed
US-20260015338-A1 TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2026-01-15 US disclosed
US-20260015362-A1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2026-01-15 US disclosed
US-20250382285-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2025-12-18 US disclosed
US-20250368631-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2025-12-04 US disclosed
US-12454521-B2 Targeted protein degradation C4 THERAPEUTICS, INC. 2025-10-28 US disclosed
US-12441740-B2 N/O-linked degrons and degronimers for protein degradation C4 THERAPEUTICS, INC. (US) 2025-10-14 US disclosed
EP-0863144-A1 IMIDAZOQUINAZOLINE DERIVATIVES Kyowa Hakko Co., Ltd. (JP) 1998-09-09 EP disclosed
EP-0639587-B1 Diene polymers and copolymers terminated with compounds having multiple-bonded nitrogen atoms and partially crosslinked with polyfunctional reagents BRIDGESTONE FIRESTONE INC (US) 1997-10-22 EP disclosed
EP-0543128-B1 Diene polymers and copolymers terminated by reaction with aromatic nitriles BRIDGESTONE FIRESTONE INC (US) 1997-01-08 EP disclosed
EP-0543305-B1 Diene polymers having reduced hysteresis and improved raw viscosity incorporating primary partial coupling and terminals formed from fused-ring polynuclear aromatic compounds or aromatic nitrile compounds BRIDGESTONE CORP (JP) 1995-10-11 EP disclosed
EP-0639587-A1 Diene polymeres and copolymers terminated with compounds having multiple-bonded nitrogen atoms and partially crosslinked with polyfunctional reagents BRIDGESTONE/FIRESTONE, INC. (US) 1995-02-22 EP disclosed
US-5310798-A Tire treads BRIDGESTONE/FIRESTONE, INC. (US) 1994-05-10 US disclosed
US-5254628-A Diene polymers having reduced hysteresis and improved raw viscosity incorporating primary partial coupling and terminals formed from aromatic nitrile compounds BRIDGESTONE CORPORATION (JP) 1993-10-19 US disclosed
EP-0543305-A1 Diene polymers having reduced hysteresis and improved raw viscosity incorporating primary partial coupling and terminals formed from fused-ring polynuclear aromatic compounds or aromatic nitrile compounds BRIDGESTONE CORPORATION (JP) 1993-05-26 EP disclosed
EP-0543128-A1 Diene polymers and copolymers terminated by reaction with aromatic nitriles BRIDGESTONE/FIRESTONE, INC. (US) 1993-05-26 EP disclosed
US-5153271-A Conjugated homo- or copolyenes, aromatic olefin copolymers endcapped by benzonitrile(or derivataives), for reduced hystersis in tire treads BRIDGESTONE/FIRESTONE, INC. (US) 1992-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368631-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS CRBN, STUB1, CUL1 KDM4E 465/4885TP53 674/4885CHRNA10 1857/4885
US-12605450-B2 C3-carbon linked glutarimide Degronimers for target protein degradation NEDD4, UBE3A, UBE3C KDM4E 1603/4885TP53 603/4885CHRNA10 1135/4885
US-12441740-B2 N/O-linked degrons and degronimers for protein degradation CRBN, CBL, STUB1 KDM4E 1099/4885TP53 119/4885CHRNA10 2630/4885
US-20260015338-A1 TARGETED PROTEIN DEGRADATION PSMC3, PSMA6, ADRM1 KDM4E 1157/4885TP53 557/4885CHRNA10 4173/4885
US-12570626-B2 Degraders and degrons for targeted protein degradation ADRM1, UCHL3, USP30 KDM4E 2163/4885TP53 367/4885CHRNA10 3685/4885
US-20260015362-A1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION CRBN, CBLC, CBL KDM4E 1492/4885TP53 185/4885CHRNA10 1459/4885
US-12454521-B2 Targeted protein degradation STUB1, MDM2, UBE3A KDM4E 781/4885TP53 180/4885CHRNA10 4709/4885
US-20250382285-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS CRBN, STUB1, CUL1 KDM4E 465/4885TP53 674/4885CHRNA10 1857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.